Literature DB >> 19556302

Antimicrobial cathelicidin polypeptide CAP11 suppresses the production and release of septic mediators in D-galactosamine-sensitized endotoxin shock mice.

Taisuke Murakami1, Toru Obata, Kyoko Kuwahara-Arai, Hiroshi Tamura, Keiichi Hiramatsu, Isao Nagaoka.   

Abstract

Endotoxin shock is a severe systemic inflammatory response that is caused by the augmented production and release of septic mediators. Among them, inflammatory cytokines such as tumor necrosis factor-alpha, IL-1beta and IL-6 play a pivotal role. In addition, anandamide, an endogenous cannabinoid and high-mobility group box-1 (HMGB1), a non-histone chromosomal protein has recently been recognized as members of septic mediators. We previously reported that cationic antibacterial polypeptide of 11-kDa (CAP11), an antimicrobial cathelicidin peptide (originally isolated from guinea pig neutrophils), potently neutralizes the biological activity of LPS and protects mice from lethal endotoxin shock. In this study, to clarify the protective mechanism of CAP11 against endotoxin shock, we evaluated the effects of CAP11 on the production and release of septic mediators in vitro and in vivo using a murine macrophage cell line RAW264.7 and a D-galactosamine-sensitized murine endotoxin shock model. LPS stimulation induced the production of inflammatory cytokines and anandamide and release of HMGB1 from RAW264.7 cells. Importantly, CAP11 suppressed the LPS-induced production and release of these mediators by RAW264.7 cells. Moreover, LPS administration enhanced the serum levels of HMGB1, anandamide and inflammatory cytokines in the endotoxin shock model. Of note, CAP11 suppressed the LPS-induced increase of these mediators in sera, and LPS binding to CD14-positive cells (peritoneal macrophages), accompanied with the increase of survival rates. Together these observations suggest that the protective action of CAP11 on endotoxin shock may be explained by its suppressive effect on the production and release of septic mediators by CD14-positive cells possibly via the inhibition of LPS binding to the targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556302     DOI: 10.1093/intimm/dxp057

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  6 in total

Review 1.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

2.  Defense peptides secreted by helminth pathogens: antimicrobial and/or immunomodulator molecules?

Authors:  Sophie Cotton; Sheila Donnelly; Mark W Robinson; John P Dalton; Karine Thivierge
Journal:  Front Immunol       Date:  2012-08-28       Impact factor: 7.561

3.  A family of helminth molecules that modulate innate cell responses via molecular mimicry of host antimicrobial peptides.

Authors:  Mark W Robinson; Sheila Donnelly; Andrew T Hutchinson; Joyce To; Nicole L Taylor; Raymond S Norton; Matthew A Perugini; John P Dalton
Journal:  PLoS Pathog       Date:  2011-05-12       Impact factor: 6.823

4.  Antimicrobial cathelicidin peptide LL-37 inhibits the LPS/ATP-induced pyroptosis of macrophages by dual mechanism.

Authors:  Zhongshuang Hu; Taisuke Murakami; Kaori Suzuki; Hiroshi Tamura; Kyoko Kuwahara-Arai; Toshiaki Iba; Isao Nagaoka
Journal:  PLoS One       Date:  2014-01-16       Impact factor: 3.240

5.  Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2.5 counteracts sepsis in rabbits.

Authors:  Sergio Bárcena-Varela; Guillermo Martínez-de-Tejada; Lukas Martin; Tobias Schuerholz; Ana Gloria Gil-Royo; Satoshi Fukuoka; Torsten Goldmann; Daniel Droemann; Wilmar Correa; Thomas Gutsmann; Klaus Brandenburg; Lena Heinbockel
Journal:  Exp Mol Med       Date:  2017-06-16       Impact factor: 8.718

6.  Immunomodulation and effects on microbiota after in ovo administration of chicken cathelicidin-2.

Authors:  Tryntsje Cuperus; Marina D Kraaij; Aldert L Zomer; Albert van Dijk; Henk P Haagsman
Journal:  PLoS One       Date:  2018-06-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.